Price Targets For Xvivo Perfusion

Stockholm Stock Exchange

Xvivo Perfusion

+15.77% (43.60)

Pareto SecuritiesDNB CarnegieHandelsbankenSEBCarnegieSEB EquitiesDanske BankDNBDanske Bank MarketsDNB MarketsBryan Garnier

Latest Target

+15.77%

320.00 SEK

Pareto Securities

Apr 9

320.00 SEK

Three Month Consensus

+15.77%

320.00 SEK

Pareto Securities

Apr 9

320.00 SEK

All Price Targets For Xvivo Perfusion

Pareto Securities

Apr 9

Target: 320.00 SEKPrice: 276.40 SEK

+15.77%

DNB Carnegie

Jan 28

Target: 300.00 SEKPrice: 276.40 SEK

+8.54%

Handelsbanken

Oct -25

Target: 300.00 SEKPrice: 276.40 SEK

+8.54%

SEB

Sep -25

Target: 430.00 SEKPrice: 276.40 SEK

+55.57%

Carnegie

Jan -25

Target: 460.00 SEKPrice: 276.40 SEK

+66.43%

SEB Equities

Oct -24

Target: 610.00 SEKPrice: 276.40 SEK

+120.69%

Danske Bank

Jul -24

Target: 560.00 SEKPrice: 276.40 SEK

+102.60%

DNB

Apr -24

Target: 468.00 SEKPrice: 276.40 SEK

+69.32%

Danske Bank Markets

Apr -24

Target: 405.00 SEKPrice: 276.40 SEK

+46.53%

DNB Markets

Jan -24

Target: 418.00 SEKPrice: 276.40 SEK

+51.23%

Bryan Garnier

Nov -23

Target: 340.00 SEKPrice: 276.40 SEK

+23.01%

About The Company

XVIVO is a medical technology company firmly rooted within medical science with more than 20 years of experience in the transplantation area.
Xvivo Perfusion